These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 12920634

  • 1. Acute renal failure following deferoxamine overdose.
    Li Volti S, Maccarone C, Li Volti G, Romeo MA.
    Pediatr Nephrol; 2003 Oct; 18(10):1078-9. PubMed ID: 12920634
    [No Abstract] [Full Text] [Related]

  • 2. Acute renal failure following deferoxamine overdose.
    Prasannan L, Flynn JT, Levine JE.
    Pediatr Nephrol; 2003 Mar; 18(3):283-5. PubMed ID: 12644925
    [Abstract] [Full Text] [Related]

  • 3. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Mar; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 4. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity.
    Porter JB, Faherty A, Stallibrass L, Brookman L, Hassan I, Howes C.
    Ann N Y Acad Sci; 1998 Jun 30; 850():483-7. PubMed ID: 9668591
    [No Abstract] [Full Text] [Related]

  • 5. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L.
    Minerva Pediatr; 2000 Apr 30; 52(4):235-41. PubMed ID: 11995208
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 7. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun 10; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 10; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 9. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N, Jahazi A, Rahim Abad HH.
    Hematology; 2012 May 10; 17(3):183-6. PubMed ID: 22664119
    [Abstract] [Full Text] [Related]

  • 10. Multimodal imaging in a case of deferoxamine-induced maculopathy.
    Gelman R, Kiss S, Tsang SH.
    Retin Cases Brief Rep; 2014 May 10; 8(4):306-9. PubMed ID: 25372534
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, Tzouvara E, Bourantas KL.
    Hematol J; 2004 May 10; 5(6):475-9. PubMed ID: 15570288
    [Abstract] [Full Text] [Related]

  • 12. Effect of iron chelator desferrioxamine on serum zinc levels in patients with beta thalassemia major.
    Sultan S, Irfan SM, Kakar J, Zeeshan R.
    Malays J Pathol; 2015 Apr 10; 37(1):35-8. PubMed ID: 25890611
    [Abstract] [Full Text] [Related]

  • 13. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N.
    Ear Nose Throat J; 2015 Dec 10; 94(12):481-5. PubMed ID: 26670754
    [Abstract] [Full Text] [Related]

  • 14. Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
    Ricchi P, Ammirabile M, Costantini S, Spasiano A, Di Matola T, Cinque P, Casale M, Filosa A, Prossomariti L.
    Ann Hematol; 2014 Mar 10; 93(3):525-7. PubMed ID: 23807253
    [No Abstract] [Full Text] [Related]

  • 15. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC.
    Br J Haematol; 2014 Nov 10; 167(3):434-6. PubMed ID: 24989901
    [No Abstract] [Full Text] [Related]

  • 16. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 17. Bull's eye maculopathy with deferoxamine.
    Bansal V, Elgarbly I, Ghanchi FD, Atkinson PL.
    Eur J Haematol; 2003 Jun 13; 70(6):420-1. PubMed ID: 12756028
    [No Abstract] [Full Text] [Related]

  • 18. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V, Kurtoglu E.
    Hematology; 2013 Jan 13; 18(1):50-5. PubMed ID: 23321010
    [Abstract] [Full Text] [Related]

  • 19. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF, Binaghi F, Putzu ML, Bragotti R, Manconi E, Urgu G, Pitzus F.
    Boll Soc Ital Cardiol; 1981 Jan 13; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec 13; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.